Spasmalin, 5 ml 25 pcs

A combined antispasmodic analgesic.

Sodium metamizole, a derivative of pyrazolone, is an analgesic-antipyretic with pronounced analgesic, antipyretic and mild anti-inflammatory action, whose mechanism is associated with inhibition of prostaglandin synthesis.

Pitophenone is a myotropic antispasmodic; it has a direct effect on the smooth muscles of internal organs and causes their relaxation.

Phenpiverinia bromide is a m-cholinoblocker and has an additional antispasmodic effect on the smooth muscles.

Indications

Active ingredient

Composition

Active ingredients:

Sodium metamizole 500 mg,

pitophenone hydrochloride 2 mg,

phenpivery bromide 0.02 mg.

How to take, the dosage

Parenteral administration is usually used in emergencies (renal or biliary colic) and when oral administration is not possible (or gastrointestinal absorption is impaired).

In adults, the average dose for intravenous administration is 2 ml. In/m is administered 2-5 ml of the solution 2-3 times per day; maximum daily dose is 10 ml. The duration of treatment is not more than 5 days.

In children doses of Spasmalin for intravenous or intravenous administration are set depending on age.

Interaction

Simultaneous use of Spasmalin with other non-opioid analgesics may lead to mutually reinforcing effects.

In concomitant use tricyclic antidepressants, oral contraceptives, allopurinol impair the metabolism of sodium metamizole in the liver and increase its toxicity.

When used concomitantly, barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effects of sodium metamizole.

Concomitant use of Spasmalin decreases the plasma concentration of cyclosporine.

When used concomitantly, sedatives and tranquilizers increase the analgesic effect of Spasmalin.

Concomitant use with histamine H1-receptor blockers, butyrophenones, phenothiazines, amantadine and quinidine may increase m-cholinolytic effects of the drugs.

Concomitant use with ethanol may mutually enhance the effects.

Special Instructions

In patients suffering from bronchial asthma, taking this drug may provoke a seizure.

Contraindications

Hypersensitivity (including to pyrazolone derivatives) inhibition of medullary hematopoiesis expressed hepatic and/or renal insufficiency glucose-6-phosphate dehydrogenase deficiency tachyarrhythmia severe angina pectoris decompensated chronic heart failure closed angle glaucoma prostatic hyperplasia (with clinical manifestations) intestinal obstruction megacolon collapse pregnancy lactation period.

Intravenous administration – infant age (less than 1 year) or body weight less than 9 kg. For intravenous administration – infant age (up to 3 months) or body weight less than 5 kg.

Hepatic/liver failure bronchial asthma susceptibility to arterial hypotension hypersensitivity to nonsteroidal anti-inflammatory drugs Complete or incomplete combination of bronchial asthma polyposis nasal and intolerance of acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs.

Side effects

Allergic reactions: urticaria (including conjunctivitis and nasopharyngeal mucosa) angioedema in rare cases – malignant exudative erythema (Stevens-Johnson syndrome) toxic epidermal necrolysis (Lyell syndrome) bronchospastic syndrome anaphylactic shock.

Urinary system disorders: renal dysfunction oliguria anuria proteinuria interstitial nephritis staining of urine in red. Cardiovascular system disorders: decreased arterial pressure.

Hematopoietic organs: thrombocytopenia leukopenia agranulocytosis (may manifest as the following symptoms: unexplained fever, chills, sore throat, difficulty swallowing stomatitis and development of vaginitis.

Anticholinergic effects: dry mouth reduced sweating paresis of accommodation tachycardia difficult urination.

Local reactions: infiltrates may occur at the injection site if administered by injection.

Overdose

Symptoms: vomiting, decreased blood pressure, drowsiness, confusion, nausea, epigastric pain, liver and kidney function disorders, seizures.

Treatment: gastric lavage, administration of activated charcoal; symptomatic therapy if necessary.

Similarities